CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells

CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells

Abstract For patients carrying BRCA1 mutations, at least one‐third develop triple negative breast cancer (TNBC). Not only is TNBC difficult to treat due to the lack of molecular target receptors, but BRCA1 mutations (BRCA1m) also result in chemotherapeutic resistance, making disease recurrence more...

Full description

Bibliographic Details
Main Authors: Rachel L. Mintz, Yeh‐Hsing Lao, Chun‐Wei Chi, Siyu He, Mingqiang Li, Chai Hoon Quek, Dan Shao, Boyuan Chen, Jing Han, Sihong Wang, Kam W. Leong
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Bioengineering & Translational Medicine
Subjects:
BRCA1
CRISPR/Cas9
PARP1
precision medicine
synthetic lethality
triple negative breast cancer
Online Access:https://doi.org/10.1002/btm2.10152

Internet

https://doi.org/10.1002/btm2.10152

Similar Items